News
SXTP
0.2250
-2.17%
-0.0050
12 Health Care Stocks Moving In Monday's Pre-Market Session
Tevogen Bio Holdings (NASDAQ:TVGN) stock rose to $ during Monday's pre-market session. The company's market cap stands at $ billion. Applied DNA Sciences stock declined by $ during the pre- market session. Tevogen Bio is one of several companies in the biotech sector.
Benzinga · 1h ago
Weekly Report: what happened at SXTP last week (0429-0503)?
Weekly Report · 05/06 12:33
60 Degrees Pharmaceuticals, Inc. (SXTP) Receives a Hold from H.C. Wainwright
TipRanks · 05/02 13:56
60 DEGREES PHARMACEUTICALS INC - IS CONTINUING PREPARATORY ACTIONS TO FACILITATE INITIATION OF PATIENT ENROLLMENT LATER IN 2024
Reuters · 05/02 11:59
Weekly Report: what happened at SXTP last week (0422-0426)?
Weekly Report · 04/29 12:42
Weekly Report: what happened at SXTP last week (0415-0419)?
Weekly Report · 04/22 12:24
Weekly Report: what happened at SXTP last week (0408-0412)?
Weekly Report · 04/15 12:14
Weekly Report: what happened at SXTP last week (0401-0405)?
Weekly Report · 04/08 12:20
60 DEGREES PHARMACEUTICALS INC - 60 DEGREES PHARMACEUTICALS TO SPONSOR PILOT STUDY OF TAFENOQUINE FOR TREATMENT OF CANINE BABESIOSIS
Reuters · 04/03 11:59
HC Wainwright & Co. Reiterates Neutral on 60 Degrees
Benzinga · 04/03 10:57
Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX), Genprex (GNPX) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
TipRanks · 04/03 10:40
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evaxion Biotech (EVAX), 60 Degrees Pharmaceuticals, Inc. (SXTP) and Genprex (GNPX)
TipRanks · 04/03 10:31
60 Degrees Q4 EPS $(0.44) Misses $(0.20) Estimate, Sales $125.68K Beat $70.00K Estimate
Benzinga · 04/02 12:01
Weekly Report: what happened at SXTP last week (0325-0329)?
Weekly Report · 04/01 12:16
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Westport Fuel Systems Inc. (NASDAQ:WPRT) posts wider-than-expected fourth-quarter loss. Krispy Kreme, Inc. And McDonald's expanded their partnership. Stoke Therapeutics, Inc., shares gained 72.6% to $11.24. C3is Inc. Reported a year-over-year increase in financial results.
Benzinga · 03/26 17:45
Why Stoke Therapeutics Shares Are Trading Higher By Around 70%; Here Are 20 Stocks Moving Premarket
Shares of Stoke Therapeutics, Inc. Rose sharply in today's pre-market trading. The company announced Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome. Check-Cap Ltd. Shares gained 38.3% to $2.67 in pre- market trading. Krispy Kreme and McDonald's USA announced expanded national partnership.
Benzinga · 03/26 12:00
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Stoke Therapeutics stock is rocketing more than 81% alongside positive Phase 1/2a studies data. The biggest pre-market stock movers on Tuesday are pharmaceutical updates, earnings reports, collaboration agreements and more. Tidal Trust II YieldMax MRNA Option Income Strategy ETF (MRNY) stock is plummeting 60% this morning.
Investorplace · 03/26 11:36
Weekly Report: what happened at SXTP last week (0318-0322)?
Weekly Report · 03/25 12:20
Weekly Report: what happened at SXTP last week (0311-0315)?
Weekly Report · 03/18 12:18
Weekly Report: what happened at SXTP last week (0304-0308)?
Weekly Report · 03/11 12:13
More
Webull provides a variety of real-time SXTP stock news. You can receive the latest news about 60 degrees pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SXTP
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.